Mitsui Pharmaceuticals, Inc.

Roche and Chugai have entered new deal making territory. It's unclear, though, whether anyone else can—or wants to—come along. by Melanie A. Senior Roche 's acquisition of 50.1% of Chugai Pharmace

Schering is betting it can crack the US market using a franchise of smaller products, rather than relying on a single blockbuster. It reckons this strategy—which few have used before—is best suited to

Tanabe Seiyaku Co. Ltd. 's planned merger with Japan's largest OTC player Taisho Pharmaceutical Co. Ltd. is yet more evidence—should anyone need it—of hard times in the Japanese pharmaceutical in